Why the study?
Does dabigatran etexilate reduce stroke or systemic embolism in patients with nonvalvular atrial fibrillation compared to warfarin?
Does dabigatran etexilate reduce stroke or systemic embolism in patients with nonvalvular atrial fibrillation compared to warfarin?
Dabigatran is an effective alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation, offering either superior efficacy (150 mg dose) or superior safety regarding major bleeding (110 mg dose).
No takes yet. Share an insight, caveat, or question.
May support dabigatran dosing choices in nonvalvular AF; leaves open need for updated head-to-head trials with other NOACs.
Paikin et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: